Patient characteristics are shown in Table 1. Compared to the non-diabetic group, diabetic patients were slightly older. The non-diabetic obese patients maintained normoglycaemia, but at the expense of hyperinsulinaemia. Levels of HOMA-IR, serum lipids and blood pressure were all comparable between the two groups.
Adiponectin, which is generally considered a protective adipokine, was elevated in diabetic patients, probably due to metformin therapy [32]. However serum MCP-1, a proinflammatory chemokine, was also elevated in these patients. These differences between the groups may be a consequence of medication (Medication regimen: None of the 44 patients were treated with α or ß-blockers. In the non-diabetic group only 4 out of the 28 patients were taking any medication [statins n=3 and ACE inhibitors n=1]. The diabetic patients were all treated with metformin [n=11] or diet alone. Additional medication included statins [n=6] and ACE inhibitors [n=5]).
Table 1 Patients’ characteristics.
Variables
|
Non-diabetic(N=28)
|
Diabetic(N=16)
|
p value
|
Gender (Male/Female)
|
4/24
|
2/14
|
-
|
Age (year)
|
39.9(12.3)
|
48.4(8.4)
|
0.01
|
BMI (kg.m-2)
|
47.7(8.9)
|
45.0(7.8)
|
0.41
|
SBP (mmHg)
|
131.4(16.3)
|
136.4(20.1)
|
0.54
|
DBP (mmHg)
|
79.2(9.1)
|
76.4(11.8)
|
0.59
|
MABP (mmHg)
|
96.6(10.1)
|
96.4(13.6)
|
0.76
|
FPG (mmol/L)
|
5.1(1.0)
|
7.7(3.2)
|
<0.01
|
Insulin (mIU/L)
|
11.3(8.1-16.1)
|
7.1(5.7-14.4)
|
0.04
|
HOMA-IR
|
2.5(1.7-3.9)
|
2.7(1.3-5.5)
|
0.66
|
TG (mmol/L)
|
1.8(1.2-2.3)
|
1.1(0.8-2.4)
|
0.12
|
Total-chol (mmol/L)
|
4.2(1.2)
|
3.8(1.1)
|
0.35
|
LDL-chol (mmol/L)
|
2.6(1.3)
|
2.2(1.0)
|
0.16
|
HDL-chol (mmol/L)
|
0.9(0.2)
|
1.0(0.2)
|
0.10
|
Adiponectin (µg/ml)
|
2.53(1.61-4.48)
|
5.2(3.9-10.4)
|
<0.01
|
IL-6 (pg/ml)
|
2.14(1.48-2.60)
|
1.9(1.3-3.0)
|
0.61
|
MCP-1 (pg/ml)
|
174.4(120.4-276.6)
|
258.6(401.5)
|
0.01
|
Data shown as mean (standard deviation) or median (interquartile range), BMI: body mass index, SBP, systolic blood pressure, DBP, diastolic blood pressure, MABP: mean arterial blood pressure, FPG, fasting plasma glucose, chol: cholesterol, TG: triglycerides, HOMA-IR, homeostasis model assessment of insulin resistance, Adiponectin, serum adiponectin, IL-6, serum interleukin-6, MCP-1, serum monocyte chemoattractant protein-1.
Tissue NE synthesis
In order to test the hypothesis that chronically elevated locally synthesized NE in the OAT and in diabetic patients may lead to vessel insensitivity to the catecholamine, the expression of the rate limiting synthetic enzyme, TH, as well as tissue and explant levels of NE were determined.
TH immunoreactivity was associated with the adipocytes, as well as with the vasculature. Lower TH density was apparent in SAT compared to OAT depots in the non-diabetic group (n=15, SAT versus OAT: 9.9 [7.9-12.9] versus 11.7 [10.0-13.9] ×104 arbitrary unit [AU], p= 0.03, Figure 1A & B). However, in the diabetic patients both depots expressed equal levels of TH. When all the patients were considered together, tissue NE levels were significantly lower in SAT compared to OAT. However, when the groups were analysed separately it was only in the non-diabetic group that this depot specific difference became apparent (n=6, SAT versus OAT: 6.1 [0.8-563.6] versus 534.8 [2.2-2819.2] pg/mg total protein, p=0.03, Figure 1C), while in diabetic patients, tissue NE was comparable in the two depots (SAT versus OAT: 194.7 [1.4-529.7] versus 335.6 [6.4-3457.7] pg/mg total protein, p=0.17). Very low concentrations of NE were detected in explant medium of both SAT and OAT (0.57[0.27-0.85] and 0.28[0.22-0.5] pg/ml respectively), suggesting a mainly autocrine/paracrine, rather than an endocrine, effect.
Low levels of AT macrophage infiltration was observed in both SAT and OAT and there was no significant difference between the depots and groups, suggesting the depot-specific difference in TH is not attributed to macrophage infiltration.
Depot- and diabetes-specific differences in AT angiogenesis
Capillary density and angiogenic capacity
As displayed in Figure 2A, in the non-diabetic group, SAT showed a significantly lower capillary number compared to OAT (p=0.01), while in the diabetic patients, no significant depot-specific difference was observed. Furthermore, capillary numbers were greater in SAT of diabetic, compared to non-diabetic, patients (p=0.05). This finding was confirmed by manually counting the capillary numbers in each section (Figure 2B). Moreover, the capillary density was calculated as the number of vessels per adipocyte, the depot-specific difference remains significant in non-diabetic group (n=7, SAT: 0.67 [0.63-0.77] versus OAT: 0.87[0.67-1.06], Figure 2C)
Angiogenic capacity was also significantly different between the depots in the non-diabetic group, with greater neovasculature in OAT compared to SAT (n=12, RV/A SAT: 8.5[8.0-9.5] versus OAT: 12.9[8.4-18.9], p=0.03, Figure 3A top panel &B). However, no significant depot-specific difference of angiogenic capacity was detected in the diabetic group (Figure 3A bottom panel &B). The angiogenic capacity of the SAT of diabetics was higher compared to that of non-diabetics (RV/A non-diabetic SAT: 8.5[8.0-9.5] versus diabetic SAT: 11.5[10.8-11.4], p=0.004, Figure 3B).
Depot- and diabetes-specific expression of genes regulating angiogenesis
Given the observed depot- and diabetes-specific differences in capillary density, we investigated the expression of genes considered essential for angiogenesis using a pathway specific array. In the non-diabetic tissue, of the 84 genes on the array, 11 were significantly up-regulated while 5 were down-regulated by > 2-fold in OAT compared to SAT. However, in the diabetic patients, only 7 out of these 11 genes were up-regulated and 9 were down-regulated in the OAT compared to SAT (Figure 4A).
Assessment of the effect of diabetes on gene expression in the two depots showed a greater number of genes upregulated in the SAT of diabetic, compared to the non-diabetic tissue (Figure 4B), especially those of epidermal growth factor (EGF) and neuropilin-1 (NRP-1). However, in the OAT only 4 genes, mainly chemokines/cytokines, were upregulated in the diabetic, compared to the non-diabetic tissue, while 3 others were lower in the OAT of diabetics compared to the non-diabetics (Figure 4B).
NE-mediated vasoconstriction
In all subjects the vasocontractile function of arterioles with comparable lumen sizes were investigated (non-diabetics: SAT versus OAT: 306.9 [215.9-440.0] versus 335.1 [233.4-430.4] μm, p=0.73, n=16, diabetics: SAT versus OAT: 278.8 [179.4-442.5] versus 330.8 [181.1-592.8] μm, p=0.72, n=10).
In the non-diabetic group, there was a significant depot specific difference in both the sensitivity to NE mediated vasoconstriction and the maximal contractile response. The arterioles from the SAT showed vasoconstriction at lower, near physiological doses of NE (at dose 10-8 M, p=0.01, dose 10-7.5 M, p=0.02, Log EC50: SAT versus OAT, -7.3[0.6] versus -6.2[0.6], Figure 5A & B). However, the maximal contractile response of the OAT vessels was higher compared to SAT vessels (SAT versus OAT: 3.65 [1.90-6.75] versus 8.03 [4.07-10.88] mN, p=0.05, Figure 5A & B).
No depot specific differences in the sensitivity or vessel tension were seen in the diabetic group (SAT versus OAT maximal vessel tension, p=0.83, Log EC50: SAT versus OAT, -6.4[0.7] versus -6.4[0.8], Figure 5A & C).
Thromboxane (U44419)-mediated vasoconstriction
To examine if other vasoconstrictors also elicited a similar depot specific difference in response, U46619, a thromboxane mimic and a powerful vasoconstrictor, was tested in the non-diabetic group. No difference in sensitivity to U46619-mediated vasoconstriction was apparent between SAT and OAT derived arterioles (Figure 5D, Log EC50: SAT versus OAT, -6.3[1.0] versus -6.8[0.7], p=0.29, n=9). However, at supra-pharmacological doses OAT arterioles exhibited greater vasoconstriction (10-6-10-5.5M, p=0.02).
Furthermore, in the comparison between thromboxane- and NE-mediated vasoconstriction in the non-diabetic group, the vessel tensions mediated by thromboxane were significantly lower compared to those mediated by NE in SAT (10-8 M to 10-6.5 M, p<0.05, Figure 5E), while there were no such differences detected in OAT, which suggests a NE-specific vessel sensitivity in SAT of non-diabetic patients.
Collagen deposition and gene expression, and NE-mediated AT fibrosis
As shown in Figure 6A, in SAT of the non-diabetic group, low levels of collagen deposition was observed surrounding the vessels and dispersed within the rest of the tissue, while OAT showed significantly higher collagen staining which was mostly near the vessels, but, also throughout the tissue. Greater fibrosis was observed in all the diabetic tissues. In SAT, collagen staining was observed around the vessels and widely dispersed within the tissue, suggesting tissue fibrosis and perhaps consequent vessel stiffness. Similar results were also found in OAT of this group. This finding was confirmed by collagen pixel area analysis and gene expression data. SAT of non-diabetic subjects displayed the lowest collagen deposition compared to OAT of the non-diabetic group and both depots of the diabetic group (Non-diabetic group: n=16, diabetic group: n=15, p<0.05, Figure 6B).
Collagen gene type Iα1 expression also showed the same trend, with SAT of non-diabetic patients having the lowest mRNA gene expression compared to OAT in the non-diabetic group and both depots in the diabetic group (n=15, Figure 6C).
Significant elevation of collagen type Iα1 mRNA expression was observed in AT incubated with 1μM NE, compared with the control [NE: 0.67(0.64-0.68) versus Control: 0.62(0.61-0.65), n=6, p=0.03], which implicates NE directly in AT remodeling.
Adipocyte size
Adipocyte size was assessed by calculating the pixel area. In the non-diabetic subjects OAT, compared to SAT, showed significantly smaller adipocytes (SAT: adipocyte number=260, 1.5[1.0-2.1] x104 μm2, OAT: adipocyte number= 286, 1.2[0.8-1.7] x104μm 2, p<0.0001). The SAT depot of diabetic patients had larger adipocytes compared to those of non-diabetic patients (diabetic versus non-diabetic SAT: 1.7 [1.1-2.5] x104μm 2 versus 1.5[1.0-2.1] x104 μm 2, p=0.04). However, in the OAT these differences were not significant (diabetic versus non-diabetic OAT: 1.2 [0.7-1.7] x104 μm 2 versus 1.2[0.8-1.7] x104 μm2, p=0.9). Furthermore, the largest adipocytes were found most frequently in the diabetic depots (Figure 7).